Author: Assoc of Chinese Stu & Scholars

为落实党的十八大、十八届三中全会关于实施创新驱动发展战略，响应国家“大众创业，万众创新”的号召，深入贯彻习近平总书记在欧美同学会成立100周年庆祝大会上的讲话及 2016年5月中共中央办公厅印发的《关于加强欧美同学会(留学人员联谊会)建设的意见》精神，发挥我会特点和优势，为实现中华民族伟大复兴“中国梦”服务。欧美同学会定于12月18日至24日在北京、广州、宁波举办第二届“百名海外名校博士创业中国行”活动。该活动在广州部分已经列为2016中国海外人才交流大会暨第十八届中国留学人员广州科技交流会活动主要内容之一。

详细活动方案及报名表等信息见附件。本次活动的报名截止日期为2016年11月30日，请及时将报名表发送到工作邮箱。会议组织方将承担您参加本次活动的交通食宿费用。

请将报名表发送至：wrsaphd@163.com

联 系 人：朱宁新

联系电话：01065122800/18810111769

联系微信：wrsa-cosa

近期到来的年轻校友们希望能多了解各行业状况和市场形势，也渴望在如何规划职业发展，培养职场能力，找到理想的工作等方面得到指导和建议。应校友们的需求，多所大学校友会联合学生组织共同举办系列职业发展交流讲座来促进校友间的职业经验与智慧的分享交流，帮助年轻校友职业发展，加深校友间的紧密联系，让大家共同进步。

生物医药行业近些年发展迅速，中美医药行业的广泛合作也促进了中国生物医药也的快速进步，所以在美国和中国生物医药各领域机会很多，但竞争也很激烈。如何在生物医药业取得一席之地，并成功驾驭职业发展是众多校友们关注的话题。我们将生物医药行业机会分析和职业发展规划作为主题来做第四期讲座。为此我们邀请到了几位生物医药领域经验丰富的专家和最近刚成功找到工作的校友来给大家做分享和互动交流。

他们的专业领域覆盖生物医药研发，临床实验，项目管理，生物统计，专利申报，以及对外合作和项目引进等。特邀分享嘉宾包括：

Frank Gan         Director, Clinical Research, Johnson & Johnson

Jimmy Hao       Attorney at Law and registered US Patent Attorney, FoxRothschild LLC

Guanghui Hu President and CEO, Admera Health

Mike Hu Senior Director, Clinical Development, Jazz Pharmaceuticals

Jerry Jing Li       Associate Principal Scientist, Global Clinical Development, Merck

Jian Liu Principal Scientist, External Discovery Chemistry, Merck

John Sun           Global Project Manager, Novartis (Moderator)

Bing Yuan         Executive Director, Oncology Business Development, Merck

时间：11/19日，星期六，下午2点到6点

地点：701 West 168th Street, Hammer Health Sciences Building, Room 401, New York, NY 10032

费用：$10 (提供饮料和snacks)

注册：因场地位置有限，请务必用此链接注册

https://www.eventbrite.com/e/29302735270

主办单位：武汉大学大纽约地区校友会，北京大学大纽约地区校友会，大纽约地区清华校友会，天津大学（北洋大学）北美校友会， 北美浙江大学校友会大纽约分会，华中科技大学大纽约校友会，中国科技大学大纽约校友会， 南京大学大纽约校友会，复旦大学美国校友会纽约分会，纽约南开校友会，中央财经大学美国校友会，交通大学美洲校友会大纽约分会，美中医药开发协会(SAPA)

协办单位：哥伦比亚大学医学院中国学生学者联谊会

嘉宾简介：

Frank Gan, Pharm. D.

Clinical Research Director

Oncology Department, Johnson & Johnson

Frank is a clinical research director working at Janssen Oncology Department. He was a bench scientist with experiences working in both academic and biopharmaceutical industry. He switched his career path from preclinical to clinical research more than 12 years ago while working at Merck. He has extensive hands-on working experiences in Phase 1, 2 and 3 clinical trials with both small molecules and biologic drug candidates, and has successfully managed several global clinical trials in metabolic disease and oncology areas while working at Merck, BMS, and Eli Lilly.

Frank received his Bachelor and Master degrees in pharmaceutical sciences from Shanghai Medical University and earned his Pharm.D. degree from Shenandoah University.

Jianming Jimmy Hao (郝建明), PhD, JD

Attorney at Law and registered US Patent Attorney, Intellectual Property (IP) Department, Fox Rothschild LLP

Mr. Hao is an attorney at law and registered U.S. patent attorney with the Intellectual Property (IP) department of Fox Rothschild LLP, a prominent national general practice law firm. With more than a decade of legal experience, he serves as counsel to many clients including Fortune 100 companies, startups, entrepreneurs, investors, and academic institutions in biotechnology and pharmaceutical industries on a broad range of business and legal issues, including patent, trademark, licensing, litigation, VC financing, and M&A. He has prosecuted thousands of patent applications nationally and internationally, including portfolios that resulted in over $47 million venture financing and $51.5 million acquisition.

Mr. Hao has provided legal representation to several notable business transactions, including Alexion Pharmaceuticals Inc.’s acquisition of Synageva BioPharma Corp (valued at $8.4 billion), Humanwell Healthcare Group and PuraCap Pharmaceutical’s acquisition of Epic Pharma (valued at $550 million), BMS’s acquisition of Amira Pharmaceuticals (valued at $475 million), licensing and collaboration deals involving companies including Merck, Alnylam, and others.

Mr. Hao received a JD from Boston College Law School, a PhD from Columbia University, an MBA from Cornell University, and a BS from Nankai University. Prior to his legal career, he conducted research on neural and heart development at Columbia University as a graduate student. During his time at Columbia University, his PhD thesis was awarded With Distinction. He later held a postdoctoral fellowship at Harvard Medical School where he conducted research on oncology, immunology, and stem cells.

Guanghui Hu, Ph.D.President & CEO， Admera Health

Dr. Guanghui Hu is the President and co-founder of Admera Health. Previously, Dr. Hu served as Vice President and Global Business Leader of Translational Genomics at GENEWIZ, Inc. Prior to joining GENEWIZ, Inc., Dr. Hu acquired over 12 years of drug development and management experience in the pharmaceutical industry at companies including Merck and GlaxoSmithKline. Dr. Hu completed postdoctoral research at the University of California Los Angeles after earning his Ph.D. from Baylor College of Medicine, holds a Master of Science degree from the Chinese Academy of Sciences, and a Bachelor of Science degree from Tsinghua University. Dr. Hu is also a member of the American Society of Clinical Oncology.

Mike Hu, Ph. D.

Senior Director

Clinical Development, Jazz Pharmaceuticals

Dr. Mike Hu, Ph.D., has over 17 years of experience in clinical and pre-clinical R&D of drugs in multiple therapeutic areas: oncology, hematology, endocrinology, metabolic, viral, and rare diseases. Dr. Hu is Senior Director at Jazz Pharmaceuticals, Clinical Development, Hematology & Oncology at Ewing, NJ, since September 2016. Prior to joining Jazz, he was Director at Novartis Oncology, Clinical Pharmacology, Global Clinical Development & Medical Affairs at East Hanover, NJ. In the past 10 years from 2006 to 2016 at Novartis Oncology, Dr. Hu contributed to 6 drugs’ full clinical development, 6 global submissions/approvals, and 11 on-market drugs’ life cycle management with multiple billion-dollar franchises. Dr. Hu was involved in hundreds of clinical trials from Phase I, II, III to IV stages. He took management and leadership roles at Clinical Pharmacology Department, Global Project Teams, Oncology Protocol Review Committee, and other forums. He was receipt of Novartis President Award, Vision Award, Global Product Strategy Business Excellence Award, and Passion/Quality/Speed Award for many times. Before joining Novartis, Dr. Hu was Principal Scientist at GSK (GlaxoSmithKline), Metabolic & Viral, Drug Metabolism & Pharmacokinetics, Center of Excellence for Drug Discovery at Research Triangle Park, NC, from 2004 to 2006. He contributed to 2 drug candidates from early discovery, candidate selection to IND stage. Before joining pharmaceutical industry, Dr. Hu was postdoctor and Research Fellow at Yale University School of Medicine, Roswell Park Cancer Institute, and State University of New York at Buffalo, with focus on molecular pharmacology, biochemistry, pharmacokinetics, pharmacodynamics, drug metabolism and transporter in oncology drugs. He received Bachelor in Pharmacy and Ph.D. in Pharmaceutical Sciences at Shenyang Pharmaceutical University, China, with international exchange program at University of Tokyo, Japan. Dr. Hu has authored 51 peer-reviewed papers, 30 congress abstracts, 5 patents, 2 proceedings, and 1 book chapter. Before joining industry, he served as editor board for 4 journals, peer reviewer for >30 journals, and consultant for 2 medical groups.

Jerry Li, Ph.D.

Associate Principal Scientist

Global Clinical Development

Merck & Co, Inc.

Dr. Jerry Li is currently focused on late phase (Phase 2 and 3) clinical trials at Biostatistics and Research Decision Sciences (BARDS) within Global Clinical Development (GCD), Merck. Dr. Li obtained his Ph.D. degree in Statistics from University of Maryland, College Park.  Dr. Li joined Merck in 2013 following two years at Center for Drug Evaluation and Research (CDER), FDA.  At Merck Dr. Li has provided critical support for clinical trial design, protocol development, statistical analysis, trial monitoring as well as authoring clinical study report (CSR) and common technical documents (CTD) for new drug application (NDA) filing to regulatory agencies worldwide including U.S. FDA and European Medicines Agency (EMA). His expertise covers multiple therapeutic areas including oncology, infectious diseases, immunology and neurosciences. Several NDAs have been approved under Dr. Li’s lead and support. Some of them were delivered under extremely tight timelines. Dr. Li has published numerous peer-reviewed articles in both discovery and clinical areas. Dr. Li holds a Ph.D. degree in molecular cell biology. Dr. Li is currently a member of 2016-2017 Executive Council of Sino-American Pharmaceutical Professionals Association (SAPA).

Jian Liu (刘建), Ph. D.

Principal Scientist

External Discovery Chemistry, Merck

Dr. Jian Liu obtained a Ph.D degree in organic chemistry from UCLA in 1998 and did postdoctoral researches afterwards at UC Irvine and University of Pennsylvania. He joined the medicinal chemistry department in Merck Research Laboratory at Rahway site in Feb, 2001. Dr. Liu has worked on and managed projects on target validation, lead identification, and lead optimization and have generated multiple clinical candidates which went into first in man, phase I, and phase II clinical trials. Dr. Liu is an expert in drug discovery for many therapeutic areas such as osteoporosis, obesity, diabetes, cardiovascular disease, rheumatoid arthritis, oncology and infection disease.  Dr. Liu has also been in charge of outsourcing effort with several external companies. Based on his research work, Dr. Liu has published over 70 peer reviewed papers, patents and patent applications. Dr. Liu had worked as a lecturer at Tsinghua University for four years before he moved to the US. He is currently the 2016-2017 president-elect of Sino-American Pharmaceutical Professionals Assoication (SAPA), He has been an executive member of SAPA during the past three years, as the director of SAPA Career Development and Continuing Education committee in 2014-15 and the director of Bussiness Development and Service Department in 2015-16. He was the chair for 2015 SAPA Career Development Workshop and 2016 SAPA Scientific Symposium.

John Sun (孙壮), PhD, MBA, PMP

Global Project Manager, Global Development Operations, Novartis

John is a passionate career planning and development practitioner and advocate. He is the Global Project Manager of Global Development Operations at Novartis. Other than his responsibilities at work, John is an active volunteer in various professional organizations, including SAPA Executive Council Member, Chair of DIA Project Management Community, and Chair of Chinese Culture Community at Novartis. He had also served as Vice-President of Novartis Toastmasters Club and the Area Director of Toastmasters International.  John had presented in various domestic and international symposia on project management and drug development.

Previously John served as Global Program Team Director in the Established Medicines Development Franchise at Novartis. Before joining Novartis, John holds positions of project management and pharmaceutical research with increased responsibilities from Whitehall-Robins, Kos Pharmaceuticals, Schering-Plough, and Sanofi-Aventis. John obtained his PhD in pharmaceutics from the Virginia Commonwealth University, MBA from the Rutgers University, and BMed from the Beijing University of Chinese Medicine. John is a certified Project Management Professional (PMP).

Bing Yuan, PhD, MBA

Executive Director and Global Lead

Oncology Business Development, Merck

Dr. Bing Yuan is an oncology business executive experienced in business development, new product strategy, global product launch and brand life cycle management. At various stages, he made key contributions to 7 oncology drugs: Keytruda, Glivec, Afinitor, Jakavi, Zykadia, Halaven and Lenvima. Dr. Yuan is currently Executive Director and Global Lead, Oncology Business Development at Merck. He is in charge of worldwide search and evaluation of clinical stage Oncology assets. In particular, he focuses on expanding Merck’s portfolio in cancer immunotherapy and strengthens Keytruda’s market position in anti-PD1 /PD-L1 class.

Before joining Merck, he held various global commercial positions with increasing responsibilities at Novartis Oncology, most recently as Executive Director and Head, Life Cycle Strategy for Glivec and Afinitor. His other roles included new product planning, early portfolio strategy, and BD evaluation. He participated in global launch of Zykadia in lung cancer and was a core deal team member that successfully in-licensed Jakavi. He was three-time Novartis Oncology President Award recipient. Before joining Novartis, he was global strategic marketing lead for Eisai’s entire Oncology portfolio. Dr. Yuan holds a BS in Biochemistry from Nanjing University, a Ph.D. in Molecular Biology from Columbia University and a MBA from Cornell University.

时间：2016年10月21日周五17:00-19:00pm

地点：The Thomas Laboratory Room 003, The Thomas Building

内容安排：

1. 山东省教育厅领导宣讲国家及山东省海外人才引进政策、人才战略计划；

2. 青岛大学人力资源处负责人介绍青岛大学人才政策及急需重点引进人才的学科领域、专业以及相关生活与工作待遇；

3. 青岛大学药学院院长、首席教授介绍青岛大学的药学、新药研发和生物医学等领域的人才需求专业，现有科研支撑平台和技术能力，未来发展战略和举措；

4. 自由交流。

热烈欢迎教师、博士后、研究生踊跃参加

（招聘会场外提供三明治和饮料等）